Literature DB >> 12183594

The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies.

Roseangela I Nwuba1, Olugbemiro Sodeinde, Chiaka I Anumudu, Yusuf O Omosun, Alexander B Odaibo, Anthony A Holder, Mark Nwagwu.   

Abstract

Malaria merozoite surface protein 1 (MSP1) is cleaved in an essential step during erythrocyte invasion. The responses of children to natural malaria infection included antibodies that inhibit this cleavage and others that block the binding of these inhibitory antibodies. There was no correlation between the titer of the antibody to the 19-kDa fragment of MSP1 and its inhibitory activity. These findings have implications for the design of MSP1-based vaccines.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12183594      PMCID： PMC128297          DOI： 10.1128/IAI.70.9.5328-5331.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  17 in total

1.  The need for assays predictive of protection in development of malaria bloodstage vaccines.

Authors:  L H Miller; M F Good; D C Kaslow
Journal:  Parasitol Today       Date:  1997-02

Review 2.  Research toward vaccines against malaria.

Authors:  L H Miller; S L Hoffman
Journal:  Nat Med       Date:  1998-05       Impact factor: 53.440

3.  Processing of the precursor to the major merozoite surface antigens of Plasmodium falciparum.

Authors:  A A Holder; J S Sandhu; Y Hillman; L S Davey; S C Nicholls; H Cooper; M J Lockyer
Journal:  Parasitology       Date:  1987-04       Impact factor: 3.234

Review 4.  Purification of Plasmodium falciparum merozoites for analysis of the processing of merozoite surface protein-1.

Authors:  M J Blackman
Journal:  Methods Cell Biol       Date:  1994       Impact factor: 1.441

Review 5.  Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria.

Authors:  A A Holder; J A Guevara Patiño; C Uthaipibull; S E Syed; I T Ling; T Scott-Finnigan; M J Blackman
Journal:  Parassitologia       Date:  1999-09

6.  Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum.

Authors:  C Uthaipibull; B Aufiero; S E Syed; B Hansen; J A Guevara Patiño; E Angov; I T Ling; K Fegeding; W D Morgan; C Ockenhouse; B Birdsall; J Feeney; J A Lyon; A A Holder
Journal:  J Mol Biol       Date:  2001-04-13       Impact factor: 5.469

7.  Expression of the 19-kilodalton carboxy-terminal fragment of the Plasmodium falciparum merozoite surface protein-1 in Escherichia coli as a correctly folded protein.

Authors:  P A Burghaus; A A Holder
Journal:  Mol Biochem Parasitol       Date:  1994-03       Impact factor: 1.759

8.  Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria.

Authors:  R A O'Donnell; T F de Koning-Ward; R A Burt; M Bockarie; J C Reeder; A F Cowman; B S Crabb
Journal:  J Exp Med       Date:  2001-06-18       Impact factor: 14.307

9.  Naturally acquired human antibodies which recognize the first epidermal growth factor-like module in the Plasmodium falciparum merozoite surface protein 1 do not inhibit parasite growth in vitro.

Authors:  J A Chappel; A F Egan; E M Riley; P Druilhe; A A Holder
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

10.  Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein.

Authors:  M J Blackman; T J Scott-Finnigan; S Shai; A A Holder
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307
View more
  38 in total

1.  Plasmodium falciparum: immunization with MSP1-42 induced non-inhibitory antibodies that have no blocking activities but enhanced the potency of inhibitory anti-MSP1-42 antibodies.

Authors:  Mark Nagata; Teri Wong; David Clements; George Hui
Journal:  Exp Parasitol       Date:  2006-11-21       Impact factor: 2.011

2.  Immunoglobulin G antibodies to merozoite surface antigens are associated with recovery from chloroquine-resistant Plasmodium falciparum in Gambian children.

Authors:  Margaret Pinder; Colin J Sutherland; Fatoumatta Sisay-Joof; Jamila Ismaili; Matthew B B McCall; Rosalyn Ord; Rachel Hallett; Anthony A Holder; Paul Milligan
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

3.  Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination.

Authors:  Kazutoyo Miura; Hong Zhou; Samuel E Moretz; Ababacar Diouf; Mahamadou A Thera; Amagana Dolo; Ogobara Doumbo; Elissa Malkin; David Diemert; Louis H Miller; Gregory E D Mullen; Carole A Long
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

4.  Antibodies to Plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria.

Authors:  Matthew B McCarra; George Ayodo; Peter O Sumba; James W Kazura; Ann M Moormann; David L Narum; Chandy C John
Journal:  Pediatr Infect Dis J       Date:  2011-12       Impact factor: 2.129

5.  Inhibitory antibodies specific for the 19-kilodalton fragment of merozoite surface protein 1 do not correlate with delayed appearance of infection with Plasmodium falciparum in semi-immune individuals in Vietnam.

Authors:  E Elsa Herdiana Murhandarwati; Lina Wang; Casilda G Black; Doan Hanh Nhan; Thomas L Richie; Ross L Coppel
Journal:  Infect Immun       Date:  2009-07-20       Impact factor: 3.441

6.  Total immunoglobulin G and IgG1 subclass levels specific for the MSP-1(19) of Plasmodium falciparum are different in individuals with either processing-inhibitory, blocking or neutral antibodies.

Authors:  Y O Omosun; S Adoro; C I Anumudu; A Odaibo; A A Holder; M Nwagwu; R I Nwuba
Journal:  Afr Health Sci       Date:  2010-06       Impact factor: 0.927

Review 7.  Immune mechanisms in malaria: new insights in vaccine development.

Authors:  Eleanor M Riley; V Ann Stewart
Journal:  Nat Med       Date:  2013-02       Impact factor: 53.440

8.  VAR2CSA Domain-Specific Analysis of Naturally Acquired Functional Antibodies to Plasmodium falciparum Placental Malaria.

Authors:  Justin Yai Alamou Doritchamou; Raul Herrera; Joan A Aebig; Robert Morrison; Vu Nguyen; Karine Reiter; Richard L Shimp; Nicholas J MacDonald; David L Narum; Michal Fried; Patrick E Duffy
Journal:  J Infect Dis       Date:  2016-05-18       Impact factor: 5.226

9.  Epitope mapping of PfCP-2.9, an asexual blood-stage vaccine candidate of Plasmodium falciparum.

Authors:  Changling Li; Rui Wang; Yuan Wu; Dongmei Zhang; Zhicheng He; Weiqing Pan
Journal:  Malar J       Date:  2010-04-12       Impact factor: 2.979

10.  Cellular responses to modified Plasmodium falciparum MSP119 antigens in individuals previously exposed to natural malaria infection.

Authors:  Christian M F Okafor; Chiaka I Anumudu; Yusuf O Omosun; Chairat Uthaipibull; Idowu Ayede; Henrietta O Awobode; Alex B Odaibo; Jean Langhorne; Anthony A Holder; Roseangela I Nwuba; Marita Troye-Blomberg
Journal:  Malar J       Date:  2009-11-23       Impact factor: 2.979
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.